153 related articles for article (PubMed ID: 18496805)
1. Monovalent and bivalent fibrin-specific MRI contrast agents for detection of thrombus.
Nair SA; Kolodziej AF; Bhole G; Greenfield MT; McMurry TJ; Caravan P
Angew Chem Int Ed Engl; 2008; 47(26):4918-21. PubMed ID: 18496805
[No Abstract] [Full Text] [Related]
2. Molecular MR imaging of human thrombi in a swine model of pulmonary embolism using a fibrin-specific contrast agent.
Spuentrup E; Katoh M; Buecker A; Fausten B; Wiethoff AJ; Wildberger JE; Haage P; Parsons EC; Botnar RM; Graham PB; Vettelschoss M; Günther RW
Invest Radiol; 2007 Aug; 42(8):586-95. PubMed ID: 17620942
[TBL] [Abstract][Full Text] [Related]
3. Strategies for increasing the sensitivity of gadolinium based MRI contrast agents.
Caravan P
Chem Soc Rev; 2006 Jun; 35(6):512-23. PubMed ID: 16729145
[TBL] [Abstract][Full Text] [Related]
4. Fibrin-targeted contrast agent for improvement of in vivo acute thrombus detection with magnetic resonance imaging.
Sirol M; Aguinaldo JG; Graham PB; Weisskoff R; Lauffer R; Mizsei G; Chereshnev I; Fallon JT; Reis E; Fuster V; Toussaint JF; Fayad ZA
Atherosclerosis; 2005 Sep; 182(1):79-85. PubMed ID: 16115477
[TBL] [Abstract][Full Text] [Related]
5. EP-2104R: a fibrin-specific gadolinium-Based MRI contrast agent for detection of thrombus.
Overoye-Chan K; Koerner S; Looby RJ; Kolodziej AF; Zech SG; Deng Q; Chasse JM; McMurry TJ; Caravan P
J Am Chem Soc; 2008 May; 130(18):6025-39. PubMed ID: 18393503
[TBL] [Abstract][Full Text] [Related]
6. Lanthanides in magnetic resonance imaging.
Bottrill M; Kwok L; Long NJ
Chem Soc Rev; 2006 Jun; 35(6):557-71. PubMed ID: 16729149
[TBL] [Abstract][Full Text] [Related]
7. Contrast agents: magnetic resonance.
Burtea C; Laurent S; Vander Elst L; Muller RN
Handb Exp Pharmacol; 2008; (185 Pt 1):135-65. PubMed ID: 18626802
[TBL] [Abstract][Full Text] [Related]
8. Mesoporous silica nanospheres as highly efficient MRI contrast agents.
Taylor KM; Kim JS; Rieter WJ; An H; Lin W; Lin W
J Am Chem Soc; 2008 Feb; 130(7):2154-5. PubMed ID: 18217764
[No Abstract] [Full Text] [Related]
9. Pushing the sensitivity envelope of lanthanide-based magnetic resonance imaging (MRI) contrast agents for molecular imaging applications.
Aime S; Castelli DD; Crich SG; Gianolio E; Terreno E
Acc Chem Res; 2009 Jul; 42(7):822-31. PubMed ID: 19534516
[TBL] [Abstract][Full Text] [Related]
10. Gold nanoparticles functionalized with gadolinium chelates as high-relaxivity MRI contrast agents.
Moriggi L; Cannizzo C; Dumas E; Mayer CR; Ulianov A; Helm L
J Am Chem Soc; 2009 Aug; 131(31):10828-9. PubMed ID: 19722661
[TBL] [Abstract][Full Text] [Related]
11. Peptide derivatized lamellar aggregates as target-specific MRI contrast agents.
Tesauro D; Accardo A; Gianolio E; Paduano L; Teixeira J; Schillén K; Aime S; Morelli G
Chembiochem; 2007 May; 8(8):950-5. PubMed ID: 17469087
[TBL] [Abstract][Full Text] [Related]
12. Linear assemblies of magnetic nanoparticles as MRI contrast agents.
Corr SA; Byrne SJ; Tekoriute R; Meledandri CJ; Brougham DF; Lynch M; Kerskens C; O'Dwyer L; Gun'ko YK
J Am Chem Soc; 2008 Apr; 130(13):4214-5. PubMed ID: 18331033
[TBL] [Abstract][Full Text] [Related]
13. Targeting exofacial protein thiols with Gd(III) complexes. An efficient procedure for MRI cell labelling.
Digilio G; Catanzaro V; Fedeli F; Gianolio E; Menchise V; Napolitano R; Gringeri C; Aime S
Chem Commun (Camb); 2009 Feb; (8):893-5. PubMed ID: 19214307
[TBL] [Abstract][Full Text] [Related]
14. In vivo molecular imaging of acute and subacute thrombosis using a fibrin-binding magnetic resonance imaging contrast agent.
Botnar RM; Perez AS; Witte S; Wiethoff AJ; Laredo J; Hamilton J; Quist W; Parsons EC; Vaidya A; Kolodziej A; Barrett JA; Graham PB; Weisskoff RM; Manning WJ; Johnstone MT
Circulation; 2004 Apr; 109(16):2023-9. PubMed ID: 15066940
[TBL] [Abstract][Full Text] [Related]
15. Magnetic resonance molecular imaging contrast agents and their application in atherosclerosis.
Mulder WJ; Strijkers GJ; Vucic E; Cormode DP; Nicolay K; Fayad ZA
Top Magn Reson Imaging; 2007 Oct; 18(5):409-17. PubMed ID: 18025995
[TBL] [Abstract][Full Text] [Related]
16. Multilocus binding increases the relaxivity of protein-bound MRI contrast agents.
Zhang Z; Greenfield MT; Spiller M; McMurry TJ; Lauffer RB; Caravan P
Angew Chem Int Ed Engl; 2005 Oct; 44(41):6766-9. PubMed ID: 16173108
[No Abstract] [Full Text] [Related]
17. Poly-beta-cyclodextrin based platform for pH mapping via a ratiometric 19F/1H MRI method.
Gianolio E; Napolitano R; Fedeli F; Arena F; Aime S
Chem Commun (Camb); 2009 Oct; (40):6044-6. PubMed ID: 19809638
[TBL] [Abstract][Full Text] [Related]
18. Tumor models and specific contrast agents for small animal imaging in oncology.
Ni Y; Wang H; Chen F; Li J; DeKeyzer F; Feng Y; Yu J; Bosmans H; Marchal G
Methods; 2009 Jun; 48(2):125-38. PubMed ID: 19328231
[TBL] [Abstract][Full Text] [Related]
19. A supramolecular approach to multivalent target-specific MRI contrast agents for angiogenesis.
Dirksen A; Langereis S; de Waal BF; van Genderen MH; Hackeng TM; Meijer EW
Chem Commun (Camb); 2005 Jun; (22):2811-3. PubMed ID: 15928766
[TBL] [Abstract][Full Text] [Related]
20. Molecular magnetic resonance imaging of atrial clots in a swine model.
Spuentrup E; Fausten B; Kinzel S; Wiethoff AJ; Botnar RM; Graham PB; Haller S; Katoh M; Parsons EC; Manning WJ; Busch T; Günther RW; Buecker A
Circulation; 2005 Jul; 112(3):396-9. PubMed ID: 16009790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
